Has anyone else seeing the announcement by the FDA on anti-TNF drugs relating to fungal infections? It certainly is not affecting the share price of arana negatively. The fact that art 621 is a small compound may read the news is a positive for the trial going forward. I am no expert in the field and am just putting the idea out for comment so all comments are welcome